 |
|
A Neuropsychological Test Battery for Use in Alzheimer Disease Clinical Trials
John Harrison, C. Psychol, PhD;
Sonia L. Minassian, DrPH;
Lisa Jenkins, PhD;
Ronald S. Black, MD;
Martin Koller, MD, MPH;
Michael Grundman, MD, MPH
Arch Neurol. 2007;64(9):1323-1329.
Objective To report the psychometric properties of an alternative instrument to the cognitive subscale of the Alzheimer's Disease Assessment Scale, a neuropsychological test battery (NTB) for measuring drug efficacy in Alzheimer disease clinical trials.
Design The NTB was evaluated in a randomized, double-blind, placebo-controlled trial of AN1792(QS-21) (synthetic β-amyloid plus an adjuvant) (300 patients) and isotonic sodium chloride solution (72 patients). The test-retest reliability of the NTB was examined, and the NTB was correlated with other cognitive (cognitive subscale of the Alzheimer's Disease Assessment Scale and Mini-Mental State Examination) and functional (Disability Assessment Scale for Dementia and Clinical Dementia Rating Sum of Boxes) measures. In addition, a factor analysis was performed on NTB components. Finally, the sensitivity of the NTB to change was assessed as a function of Mini-Mental State Examination performance.
Results The NTB had high test-retest reliability at 6 (Pearson product moment correlation [r] = 0.92) and 12 (r = 0.88) months. Internal consistency was high (Cronbach  = 0.84). The correlations between the NTB z score and scores on traditional measures of cognition and function were significantly different from 0 (P < .001). A factor analysis yielded "memory" and "executive function" factors. The NTB z score declined linearly over 1 year in patients receiving placebo and, in contrast to the Alzheimer's Disease Assessment Scale cognitive subscale, demonstrated similar declines in patients with high (21-26) and low (15-20) Mini-Mental State Examination scores at baseline.
Conclusions The NTB exhibits excellent psychometric properties and seems to be a reliable and sensitive measure of cognitive change in patients with mild to moderate Alzheimer disease. The psychometric properties of the NTB suggest that it may have particular utility in evaluating drug efficacy in clinical trials in which patients with mild Alzheimer disease are included.
Author Affiliations: CPC Pharma Services, Warminster, England (Dr Harrison); Elan Pharmaceuticals, San Diego, California (Drs Minassian, Koller, and Grundman); and Wyeth Research, Collegeville, Pennsylvania (Drs Jenkins and Black).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED LETTER
Notice of Failure to Disclose Financial Interest: "A Neuropsychological Test Battery for Use in Alzheimer Disease Clinical Trials" (Arch Neurol. 2007;64[9]:1323-1329)
John Harrison
Arch Neurol. 2008;65(7):992.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway et al.
Neurology 2011;77:1253-1262.
ABSTRACT
| FULL TEXT
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway et al.
Neurology 2009;73:2061-2070.
ABSTRACT
| FULL TEXT
Toward Establishing Guidelines for Evaluating Cognitive Enhancement With Complementary and Alterative Medicines
Solomon and Michalczuk
Eval Health Prof 2009;32:370-392.
ABSTRACT
Notice of Failure to Disclose Financial Interest: "A Neuropsychological Test Battery for Use in Alzheimer Disease Clinical Trials" (Arch Neurol. 2007;64[9]:1323-1329)
Harrison
Arch Neurol 2008;65:992-992.
FULL TEXT
|
